PROTACs are heterobifunctional small molecules that simultaneously bind a target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target. Major progress in developing potent and specific PROTACs has recently been reported, invigorating prospects for novel PROTAC-based therapies.
Change history
23 September 2015
In the version of this article originally published, the protein ERRα was mislabeled as BRD4 in Figure 1 and its legend, and the citation of the figure in the text was misplaced. These errors have been corrected in the HTML and PDF versions of the article.
References
Sakamoto, K.M. et al. Proc. Natl. Acad. Sci. USA 98, 8554–8559 (2001).
Buckley, D.L. & Crews, C.M. Angew. Chem. Int. Edn. Engl. 53, 2312–2330 (2014).
Buckley, D.L. et al. ACS Chem. Biol. doi:10.1021/acschembio.5b00442 (2015).
Lu, J. et al. Chem. Biol. 22, 755–763 (2015).
Winter, G.E. et al. Science 348, 1376–1381 (2015).
Zengerle, M., Chan, K.H. & Ciulli, A. ACS Chem. Biol. doi:10.1021/acschembio.5b00216 (2015).
Bondeson, D.P. et al. Nat. Chem. Biol. 11, 611–617 (2015).
Ito, T.H. et al. Science 327, 1345–1350 (2010).
Krönke, J. et al. Science 343, 301–305 (2014).
Lu, G. et al. Science 343, 305–309 (2014).
Gandhi, A.K. et al. Br. J. Haematol. 164, 811–821 (2014).
Fischer, E.S. et al. Nature 512, 49–53 (2014).
Chamberlain, P.P. et al. Nat. Struct. Mol. Biol. 21, 803–809 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J.D. is co-founder of a company (Cleave Biosciences) that is developing therapeutics based on targeting enzymes in the ubiquitin-proteasome pathway. R.J.D. also holds stock in Cleave Biosciences and serves as a consultant and member of their Scientific Advisory Board.
Rights and permissions
About this article
Cite this article
Deshaies, R. Prime time for PROTACs. Nat Chem Biol 11, 634–635 (2015). https://doi.org/10.1038/nchembio.1887
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1887
- Springer Nature America, Inc.
This article is cited by
-
Generation of a live attenuated influenza A vaccine by proteolysis targeting
Nature Biotechnology (2022)
-
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
Acta Pharmacologica Sinica (2020)
-
Biological roles of LSD1 beyond its demethylase activity
Cellular and Molecular Life Sciences (2020)
-
Structural basis of Cullin 2 RING E3 ligase regulation by the COP9 signalosome
Nature Communications (2019)
-
PROTACs: great opportunities for academia and industry
Signal Transduction and Targeted Therapy (2019)